These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25384899)

  • 21. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
    Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
    Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist.
    Bungay PJ; Tweedy S; Howe DC; Gibson KR; Jones HM; Mount NM
    Drug Metab Dispos; 2011 Aug; 39(8):1396-405. PubMed ID: 21543556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
    Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
    Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using a tritiated compound to elucidate its preclinical metabolic and excretory pathways in vivo: exploring tritium exchange risk.
    Shaffer CL; Gunduz M; Thornburgh BA; Fate GD
    Drug Metab Dispos; 2006 Sep; 34(9):1615-23. PubMed ID: 16790552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs.
    Zhang D; Raghavan N; Chen SY; Zhang H; Quan M; Lecureux L; Patrone LM; Lam PY; Bonacorsi SJ; Knabb RM; Skiles GL; He K
    Drug Metab Dispos; 2008 Feb; 36(2):303-15. PubMed ID: 17984286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The identification of lobeglitazone metabolites in rat liver microsomes and the kinetics of the in vivo formation of the major metabolite M1 in rats.
    Lee JH; Ahn SH; Maeng HJ; Lee W; Kim DD; Chung SJ
    J Pharm Biomed Anal; 2015 Nov; 115():375-82. PubMed ID: 26275726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
    Smith BJ; Pithavala Y; Bu HZ; Kang P; Hee B; Deese AJ; Pool WF; Klamerus KJ; Wu EY; Dalvie DK
    Drug Metab Dispos; 2014 May; 42(5):918-31. PubMed ID: 24608633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition and biotransformation of the acetylenic retinoid tazarotene in humans.
    Attar M; Yu D; Ni J; Yu Z; Ling KH; Tang-Liu DD
    J Pharm Sci; 2005 Oct; 94(10):2246-55. PubMed ID: 16136553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Species differences in the biotransformation of an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist: the effects of distinct glucuronide metabolites on overall compound disposition.
    Shaffer CL; Gunduz M; Ryder TF; O'Connell TN
    Drug Metab Dispos; 2010 Feb; 38(2):292-301. PubMed ID: 19910512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling.
    Kamimura H; Ito S; Chijiwa H; Okuzono T; Ishiguro T; Yamamoto Y; Nishinoaki S; Ninomiya SI; Mitsui M; Kalgutkar AS; Yamazaki H; Suemizu H
    Xenobiotica; 2017 May; 47(5):382-393. PubMed ID: 27389028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life.
    Pike KG; Allen JV; Caulkett PW; Clarke DS; Donald CS; Fenwick ML; Johnson KM; Johnstone C; McKerrecher D; Rayner JW; Walker RP; Wilson I
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3467-70. PubMed ID: 21515051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.
    Zamek-Gliszczynski MJ; Abraham TL; Alberts JJ; Kulanthaivel P; Jackson KA; Chow KH; McCann DJ; Hu H; Anderson S; Furr NA; Barbuch RJ; Cassidy KC
    Drug Metab Dispos; 2013 Apr; 41(4):714-26. PubMed ID: 23305709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
    Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
    Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of capravirine as a CYP3A probe substrate: in vitro and in vivo metabolism of capravirine in rats and dogs.
    Bu HZ; Zhao P; Kang P; Pool WF; Wu EY; Shetty BV
    Drug Metab Dispos; 2007 Sep; 35(9):1593-602. PubMed ID: 17567732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elucidating the mechanism of cytochrome P450-mediated pyrimidine ring conversion to pyrazole metabolites with the BACE1 inhibitor GNE-892 in rats.
    Takahashi R; Ma S; Deese A; Yue Q; Kim-Kang H; Yi Y; Siu M; Hunt KW; Kallan NC; Hop CE; Liu X; Khojasteh SC
    Drug Metab Dispos; 2014 May; 42(5):890-8. PubMed ID: 24595682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.
    Pfefferkorn JA; Tu M; Filipski KJ; Guzman-Perez A; Bian J; Aspnes GE; Sammons MF; Song W; Li JC; Jones CS; Patel L; Rasmusson T; Zeng D; Karki K; Hamilton M; Hank R; Atkinson K; Litchfield J; Aiello R; Baker L; Barucci N; Bourassa P; Bourbonais F; D'Aquila T; Derksen DR; MacDougall M; Robertson A
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7100-5. PubMed ID: 23089526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of exposure of metabolites in preclinical species and humans at steady state from the single-dose radiolabeled absorption, distribution, metabolism, and excretion studies: a case study.
    Prakash C; Li Z; Orlandi C; Klunk L
    Drug Metab Dispos; 2012 Jul; 40(7):1308-20. PubMed ID: 22474055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
    Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.